Summary: "Once approved, the drug may not be marketed or promoted for so-called "off-label" uses – i.e., any use not specified in an application and approved by FDA. Pfizer promoted the sale of Bextra for several uses and dosages that the FDA specifically declined to approve due to safety concerns."<p>Bextra was approved: "for the treatment of osteoarthritis, adult rheumatoid arthritis, and primary dysmenorrhea." [0]<p>But was marketed for: "In such documents, PHARMACIA marketing team stated as the “intended” use and message for Bextra that Bextra was for “acute pain.”" [1]<p>[0]: <a href="https://en.wikipedia.org/wiki/Valdecoxib#Uses_until_2005" rel="nofollow">https://en.wikipedia.org/wiki/Valdecoxib#Uses_until_2005</a><p>[1]: <a href="https://archive.is/20091207084948/http://www.usdoj.gov/usao/ma/Press%20Office%20-%20Press%20Release%20Files/Sept2009/PharmaciaPlea.html#selection-361.247-361.376" rel="nofollow">https://archive.is/20091207084948/http://www.usdoj.gov/usao/...</a>